(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 November 2014 (13.11.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/180889 A8

(51) International Patent Classification:
C12N 15/113 (2010.01) *C07K 14/47* (2006.01)
A61K 38/17 (2006.01)

(21) International Application Number:
PCT/EP2014/059315

(22) International Filing Date:
7 May 2014 (07.05.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
13382167.8 7 May 2013 (07.05.2013) EP

(71) Applicant: **FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON** [ES/ES]; Passeig Vall d'Hebron 119, Hospital Universitari de la Vall d'Hebron, Edifici Maternoinfantil, planta 14, E-08035 Barcelona (ES).

(72) Inventors: **SOUCEK, Laura**; Fundació Privada Institut d'Investigació Oncològica de Vall Hebron, Passeig Vall d'Hebron 119, Hospital Universitari de la Vall d'Hebron, Edifici Maternoinfantil, planta 14, E-08035 Barcelona (ES). **BEAULIEU, Marie-Eve**; Fundació Privada Institut d'Investigació Oncològica de Vall Hebron, Passeig Vall d'Hebron 119, Hospital Universitari de la Vall d'Hebron, Edifici Maternoinfantil, planta 14, E-08035 Barcelona (ES).

(74) Agent: **ALCONADA RODRÍGUEZ, Agustín**; ABG Patentes, S.L., Avenida de Burgos, 16D, Edificio Euromor, E-28036 Madrid (ES).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

— *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

(48) Date of publication of this corrected version:
18 June 2015

(15) Information about Correction:
see Notice of 18 June 2015

WO 2014/180889 A8

(54) Title: METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER

(57) Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.